Dashboard
1
High Management Efficiency with a high ROE of 94.58%
2
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 32.34
3
Poor long term growth as Operating profit has grown by an annual rate 3.69% of over the last 5 years
4
Positive results in Dec 24
5
With ROE of 39.17%, it has a Very Attractive valuation with a 4.48 Price to Book Value
6
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
HKD 128,532 Million ()
11.00
NA
87.77%
-0.24
36.44%
3.52
Revenue and Profits:
Net Sales:
8,551 Million
(Quarterly Results - Jun 2021)
Net Profit:
8,715 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-21.21%
0%
-21.21%
6 Months
19.51%
0%
19.51%
1 Year
100.59%
0%
100.59%
2 Years
104.82%
0%
104.82%
3 Years
49.45%
0%
49.45%
4 Years
20.35%
0%
20.35%
5 Years
1.04%
0%
1.04%
Sino Biopharmaceutical Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
14.51%
EBIT Growth (5y)
3.69%
EBIT to Interest (avg)
32.34
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.63
Tax Ratio
25.58%
Dividend Payout Ratio
65.98%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
134.35%
ROE (avg)
94.58%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
4.48
EV to EBIT
28.74
EV to EBITDA
22.18
EV to Capital Employed
5.11
EV to Sales
4.94
PEG Ratio
0.07
Dividend Yield
98.70%
ROCE (Latest)
17.78%
ROE (Latest)
39.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'21 - YoY
Jun'21
Jun'20
Change(%)
Net Sales
8,550.90
7,026.80
21.69%
Operating Profit (PBDIT) excl Other Income
2,442.00
2,582.50
-5.44%
Interest
90.90
91.70
-0.87%
Exceptional Items
64.10
-483.50
113.26%
Consolidate Net Profit
8,715.00
1,053.80
727.01%
Operating Profit Margin (Excl OI)
255.90%
314.80%
-5.89%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2021 is 21.69% vs -3.21% in Jun 2020
Consolidated Net Profit
YoY Growth in quarter ended Jun 2021 is 727.01% vs -20.68% in Jun 2020
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
31,297.40
28,950.30
8.11%
Operating Profit (PBDIT) excl Other Income
8,135.00
7,488.20
8.64%
Interest
320.00
547.20
-41.52%
Exceptional Items
-1,385.80
-157.50
-779.87%
Consolidate Net Profit
5,187.50
5,097.00
1.78%
Operating Profit Margin (Excl OI)
215.10%
220.10%
-0.50%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 8.11% vs -4.34% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 1.78% vs -2.99% in Dec 2023
About Sino Biopharmaceutical Ltd. 
Sino Biopharmaceutical Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






